These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 10581168

  • 1. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
    Wall NR, Mohammad RM, Nabha SM, Pettit GR, Al-Katib AM.
    Biochem Biophys Res Commun; 1999 Dec 09; 266(1):76-80. PubMed ID: 10581168
    [Abstract] [Full Text] [Related]

  • 2. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A.
    Clin Cancer Res; 1998 May 09; 4(5):1337-43. PubMed ID: 9607595
    [Abstract] [Full Text] [Related]

  • 3. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.
    Wall NR, Mohammad RM, Al-Katib AM.
    Leuk Res; 1999 Oct 09; 23(10):881-8. PubMed ID: 10573132
    [Abstract] [Full Text] [Related]

  • 4. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 09; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 5. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
    Grant S, Turner AJ, Freemerman AJ, Wang Z, Kramer L, Jarvis WD.
    Exp Cell Res; 1996 Oct 10; 228(1):65-75. PubMed ID: 8892972
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul 10; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
    Grant S, Jarvis WD, Swerdlow PS, Turner AJ, Traylor RS, Wallace HJ, Lin PS, Pettit GR, Gewirtz DA.
    Cancer Res; 1992 Nov 15; 52(22):6270-8. PubMed ID: 1423273
    [Abstract] [Full Text] [Related]

  • 8. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A, Lazarus HM, Hartman P, Jacobberger JW, Whitacre C, Gerson SL, Ksenich P, Cooper BW, Frisa PS, Gottlieb M, Murgo AJ, Remick SC.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [Abstract] [Full Text] [Related]

  • 9. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M, Al-Katib A.
    Anticancer Drugs; 1998 Feb 01; 9(2):149-56. PubMed ID: 9510501
    [Abstract] [Full Text] [Related]

  • 10. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
    Wall NR, Mohammad RM, Reddy KB, Al-Katib AM.
    Int J Mol Med; 2000 Feb 01; 5(2):165-71. PubMed ID: 10639596
    [Abstract] [Full Text] [Related]

  • 11. Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis.
    Bartimole TM, Vrana JA, Freemerman AJ, Jarvis WD, Reed JC, Boise LH, Grant S.
    Cell Death Differ; 1997 May 01; 4(4):294-303. PubMed ID: 16465244
    [Abstract] [Full Text] [Related]

  • 12. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
    Majlessipour F, Avramis IA, Kwock R, Weinberg KI, Avrami VI.
    Anticancer Res; 2002 May 01; 22(3):1361-8. PubMed ID: 12168812
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM.
    Clin Cancer Res; 1998 May 01; 4(5):1305-14. PubMed ID: 9607591
    [Abstract] [Full Text] [Related]

  • 15. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
    Ali MA, Rosati R, Pettit GR, Kalemkerian GP.
    Anticancer Res; 1998 May 01; 18(2A):1021-6. PubMed ID: 9615758
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM.
    Clin Cancer Res; 2000 Mar 01; 6(3):825-8. PubMed ID: 10741703
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic and apoptotic effects of prenylflavonoid artonin B in human acute lymphoblastic leukemia cells.
    Lee CC, Lin CN, Jow GM.
    Acta Pharmacol Sin; 2006 Sep 01; 27(9):1165-74. PubMed ID: 16923337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.